Huaren Pharmaceutical(300110)2025-01-24 12:02Financial Projections - The estimated net profit for 2024 is projected to be a loss of between 118,000.00 and 138,000.00 thousand RMB, representing a decline of 727.45% to 833.80% compared to the previous year's profit of 18,806.30 thousand RMB [2]. - The net profit after deducting non-recurring gains and losses is expected to be a loss of between 119,000.00 and 139,000.00 thousand RMB, a decrease of 814.28% to 934.33% from last year's profit of 16,660.04 thousand RMB [2]. Impairment and Provisions - The company plans to fully provision for credit impairment losses on receivables from China National Pharmaceutical Group Co., Ltd., amounting to 134,780.14 thousand RMB, pending final audit confirmation [4]. - The goodwill impairment for Anhui Hengxing Pharmaceutical Co., Ltd. is estimated to be between 3,000 thousand RMB and 9,000 thousand RMB, subject to assessment and audit [5]. Revenue and Profitability Challenges - Sales prices of some products have decreased due to pharmaceutical pricing policies, leading to a decline in revenue and gross profit compared to the previous year [5]. Strategic Initiatives - The company is committed to enhancing Anhui Hengxing's profitability and sustainable development through capacity improvement, sales channel expansion, and new product development [5]. - The management expresses confidence in future operational development, focusing on core business and accelerating measures to turn losses into profits [5]. Financial Reporting - The financial data presented is preliminary and unaudited, with detailed figures to be disclosed in the 2024 annual report [6].